Sequoia Financial Advisors LLC Has $1.77 Million Stock Position in Sanofi $SNY

Sequoia Financial Advisors LLC raised its stake in Sanofi (NASDAQ:SNY) by 45.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,712 shares of the company’s stock after acquiring an additional 11,505 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,769,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Morgan Stanley increased its holdings in shares of Sanofi by 20.4% in the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after purchasing an additional 1,540,271 shares in the last quarter. Invesco Ltd. lifted its holdings in Sanofi by 5.4% during the 4th quarter. Invesco Ltd. now owns 6,110,874 shares of the company’s stock worth $296,133,000 after buying an additional 313,327 shares in the last quarter. Raymond James Financial Inc. boosted its position in Sanofi by 81.3% in the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after buying an additional 2,635,867 shares during the last quarter. Franklin Resources Inc. boosted its position in Sanofi by 29.7% in the 4th quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after buying an additional 1,168,339 shares during the last quarter. Finally, Mondrian Investment Partners LTD increased its stake in shares of Sanofi by 23.5% in the 4th quarter. Mondrian Investment Partners LTD now owns 4,495,348 shares of the company’s stock valued at $217,845,000 after buying an additional 856,742 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SNY has been the topic of several research reports. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Monday, April 20th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research report on Wednesday, July 8th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Citigroup reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $49.50.

Sanofi Price Performance

Sanofi stock opened at $43.68 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $105.90 billion, a P/E ratio of 12.20, a PEG ratio of 1.10 and a beta of 0.34. The business has a 50-day moving average of $43.30 and a 200-day moving average of $45.56. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.